NIOX Group Plc (CSSPF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NIOX Group Plc (CSSPF) trades at $0.75 with AI Score 47/100 (Grade C). NIOX Group Plc is a diagnostics company specializing in point-of-care fractional exhaled nitric oxide (FeNO) measurement products, primarily for asthma management. Market cap: $315.65M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for CSSPF: CSSPF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CSSPF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CSSPF: the 1 perspectives are evenly split.
How is this calculated? →NIOX Group Plc (CSSPF) Healthcare & Pipeline Overview
NIOX Group Plc develops and commercializes point-of-care diagnostic products for fractional exhaled nitric oxide (FeNO) measurement, crucial for asthma management. Headquartered in Oxford, UK, the company's NIOX VERO system provides a portable, non-invasive solution, establishing its presence in the global medical devices market focused on respiratory health diagnostics.
What Is the Investment Thesis for CSSPF?
NIOX Group Plc presents an investment thesis centered on its specialized diagnostic technology for respiratory health, particularly within asthma management. The company's NIOX VERO system, offering point-of-care fractional exhaled nitric oxide (FeNO) measurement, addresses a critical need for objective, non-invasive airway inflammation assessment. With a market capitalization of $315.65M and a P/E ratio of 35.2, the company demonstrates profitability with a 14.4% profit margin and a strong 60.8% gross margin, indicating efficient operations and pricing power for its specialized product. The 2.67% dividend yield suggests a commitment to shareholder returns. Growth catalysts include the increasing global prevalence of respiratory diseases, the rising demand for personalized medicine, and the continued adoption of point-of-care diagnostics. The non-invasive nature and portability of NIOX VERO enhance its appeal for broader clinical integration. While the negative Beta of -0.04 suggests low correlation with market movements, the company's position in a niche, yet growing, segment of the medical devices market provides a foundation for potential value appreciation as FeNO testing gains wider clinical acceptance and reimbursement.
Based on FMP financials and quantitative analysis
CSSPF Key Highlights
- Market capitalization stands at $0.34 billion, reflecting its valuation within the medical devices sector.
- Achieved a P/E ratio of 35.2, indicating market expectations for future earnings relative to its current share price.
- Maintained a robust gross margin of 60.8%, demonstrating strong cost control and pricing power for its specialized diagnostic products.
- Reported a profit margin of 14.4%, showcasing its ability to convert revenue into net income efficiently.
- Offers a dividend yield of 2.67%, providing income to shareholders.
Who Are CSSPF's Competitors?
CSSPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
| OWLT Owlet, Inc. | $5.91 | +2.60% | $106.94M | 58 |
| NXL Nexalin Technology, Inc. | $0.35 | -3.07% | $7.20M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CSSPF's Key Strengths?
- Proprietary point-of-care FeNO diagnostic technology (NIOX VERO).
- Non-invasive and portable system enhances patient comfort and clinical utility.
- Strong gross margin (60.8%) and profit margin (14.4%) indicate operational efficiency.
- Addresses a critical need in respiratory health management, particularly asthma.
What Are CSSPF's Weaknesses?
- Trades on the OTC Other tier, implying potential liquidity and transparency challenges.
- Limited public disclosure status (Unknown) for financial reporting.
- Relatively small employee base (91 employees) compared to larger medical device companies.
- Niche product focus, potentially limiting broader market diversification.
What Could Drive CSSPF Stock Higher?
- Broader clinical guideline updates that further emphasize the utility of FeNO testing in asthma management could drive increased adoption of NIOX VERO globally.
- Continued expansion of distribution channels and market penetration in key international markets for respiratory diagnostics.
- Positive outcomes from ongoing clinical studies or real-world evidence demonstrating enhanced patient outcomes with FeNO-guided therapy.
- Strategic partnerships with larger healthcare organizations or pharmaceutical companies to expand product reach and integration.
What Are the Key Risks for CSSPF?
- Rich valuation — a P/E of 35.2 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Slowdown in the adoption rate of FeNO diagnostic technology among healthcare providers, limiting market growth.
- Intense competition from existing and new players in the broader respiratory diagnostics market, potentially impacting market share.
- Adverse changes in regulatory policies or reimbursement landscapes for diagnostic medical devices in key operating regions.
- Risks associated with trading on the OTC Other tier, including limited liquidity, potential for price volatility, and reduced transparency.
- Dependence on the continued relevance and technological superiority of the NIOX VERO system in a rapidly evolving medical technology landscape.
What Are the Growth Opportunities for CSSPF?
- Expansion in Emerging Markets: The global prevalence of asthma and other respiratory conditions is significant, particularly in emerging economies where access to advanced diagnostics may be limited. NIOX Group Plc can target these markets by leveraging the portability and non-invasive nature of NIOX VERO, potentially establishing distribution networks and educational programs. The market for respiratory diagnostics in emerging regions is projected to grow substantially, offering a long-term opportunity over the next 5-10 years as healthcare infrastructure develops and awareness increases.
- Broader Clinical Adoption of FeNO Testing: While FeNO testing is recognized in guidelines for asthma management, its full adoption across all relevant clinical settings is still evolving. NIOX Group Plc has an opportunity to drive broader acceptance and integration of FeNO measurement into routine clinical practice, beyond specialist pulmonology clinics, including primary care and pediatric settings. This involves continued clinical evidence generation, physician education, and advocacy for inclusion in more comprehensive treatment algorithms, with a timeline of 3-7 years for significant market penetration.
- Development of New Applications for FeNO Technology: Beyond asthma, FeNO measurement could have diagnostic or monitoring utility in other inflammatory airway diseases or conditions impacted by nitric oxide pathways. Research into these new applications, potentially including chronic obstructive pulmonary disease (COPD) exacerbations or specific allergic conditions, could unlock entirely new market segments. Investing in R&D for these expanded indications could create new revenue streams, with a potential timeline of 5-10 years for clinical validation and commercialization.
- Integration with Digital Health Platforms: The trend towards digital health and remote patient monitoring offers a significant growth avenue. Integrating NIOX VERO data with telehealth platforms, electronic health records, or patient management apps could enhance its utility, improve patient adherence, and provide longitudinal data for better disease management. This would position NIOX Group Plc as a key player in connected respiratory care, appealing to a tech-savvy healthcare market. This opportunity could materialize within the next 2-5 years as digital health infrastructure matures.
- Strategic Partnerships and Acquisitions: Collaborating with larger pharmaceutical companies, healthcare providers, or other diagnostic firms could accelerate market penetration and product development. Strategic partnerships could facilitate access to broader distribution channels, enhance R&D capabilities, or provide capital for expansion. Furthermore, targeted acquisitions of complementary technologies or smaller diagnostic companies could expand NIOX Group Plc's product portfolio or market reach, strengthening its competitive position over a 3-7 year horizon.
What Opportunities Does CSSPF Have?
- Increasing global focus on respiratory health and air pollution drives demand for diagnostics.
- Expansion into new geographic markets, especially emerging economies.
- Broader clinical adoption of FeNO testing in primary care and pediatric settings.
- Potential for new applications of FeNO technology beyond asthma.
What Threats Does CSSPF Face?
- Intense competition from larger, more diversified medical device companies.
- Regulatory changes or reimbursement policy shifts affecting diagnostic devices.
- Technological advancements by competitors could render current products less competitive.
- Market acceptance and adoption rates of FeNO testing could be slower than anticipated.
What Are CSSPF's Competitive Advantages?
- Specialized FeNO Technology: Proprietary technology for accurate and reliable fractional exhaled nitric oxide measurement at the point of care.
- Non-Invasive and Portable Solution: The NIOX VERO system offers a significant advantage in patient comfort and ease of use, facilitating broader adoption in diverse clinical settings.
- Established Clinical Validation: FeNO measurement is recognized in international guidelines for asthma management, lending credibility and clinical acceptance to NIOX Group Plc's products.
- Global Distribution Network: Established presence in multiple countries allows for widespread access to its diagnostic devices.
What Does CSSPF Do?
NIOX Group Plc, incorporated in 2006 and formerly known as Circassia Group Plc until its name change in September 2022, is a diagnostics and management company headquartered in Oxford, the United Kingdom. The company specializes in providing point-of-care fractional exhaled nitric oxide (FeNO) diagnosis and management products across the globe. Its core offering is the NIOX VERO, a highly portable system designed for the non-invasive measurement of nitric oxide in human breath. This technology plays a critical role in the diagnosis and ongoing management of respiratory conditions, particularly asthma, by assessing airway inflammation. The company's evolution reflects a strategic focus on diagnostic solutions that empower healthcare professionals with immediate, actionable insights at the point of care. The NIOX VERO system represents a significant advancement in respiratory diagnostics, moving beyond traditional, often subjective, methods to offer an objective biomarker for airway inflammation. This non-invasive approach enhances patient comfort and facilitates broader adoption in various clinical settings, from specialist clinics to general practitioner offices. By providing a precise and rapid measurement of FeNO, NIOX Group Plc enables clinicians to make more informed decisions regarding asthma diagnosis, treatment initiation, and ongoing therapy adjustments, thereby optimizing patient outcomes. The company's commitment to developing user-friendly, portable diagnostic tools underscores its dedication to improving access to advanced respiratory care worldwide. Its operations span a global reach, distributing its specialized products to healthcare providers who prioritize accurate and efficient management of respiratory diseases. The increasing global focus on respiratory health and air pollution further amplifies the relevance and potential demand for NIOX Group Plc's specialized diagnostic offerings.
What Products and Services Does CSSPF Offer?
- Develops and commercializes point-of-care diagnostic products.
- Specializes in fractional exhaled nitric oxide (FeNO) measurement.
- Offers the NIOX VERO system, a portable device for non-invasive breath analysis.
- NIOX VERO measures nitric oxide in human breath to assess airway inflammation.
- Products are used globally for the diagnosis and management of respiratory conditions, primarily asthma.
- Provides tools that enable healthcare professionals to make informed decisions regarding asthma treatment.
- Focuses on improving access to advanced, objective respiratory diagnostics.
How Does CSSPF Make Money?
- Sells NIOX VERO diagnostic devices directly to healthcare providers, clinics, and hospitals worldwide.
- Generates recurring revenue from the sale of consumables (e.g., mouthpieces, filters) required for each FeNO test.
- Provides ongoing service and maintenance contracts for its diagnostic systems.
- Potentially earns revenue from training and educational services related to FeNO testing.
What Industry Does CSSPF Operate In?
NIOX Group Plc operates within the Medical Devices industry, a segment of the broader Healthcare sector, specifically focusing on respiratory diagnostics. The company's niche is the development and commercialization of point-of-care fractional exhaled nitric oxide (FeNO) measurement devices, such as the NIOX VERO system. This positions NIOX Group Plc at the intersection of several significant industry trends: the increasing global burden of respiratory diseases like asthma, the growing demand for non-invasive diagnostic tools, and the shift towards personalized medicine and point-of-care testing. The competitive landscape for respiratory diagnostics includes larger medical device manufacturers and specialized diagnostic companies. NIOX Group Plc differentiates itself through its dedicated focus on FeNO technology, which provides an objective biomarker for airway inflammation, offering a unique value proposition in a market increasingly seeking precise and efficient diagnostic solutions. The rising awareness of air quality and its impact on respiratory health further amplifies the relevance of the company's diagnostic offerings.
Who Are CSSPF's Key Customers?
- Pulmonologists and respiratory specialists in hospitals and private practices.
- General practitioners and family doctors managing patients with asthma.
- Pediatricians and pediatric clinics for diagnosing and monitoring childhood asthma.
- Allergists and immunologists using FeNO to assess allergic airway inflammation.
- Research institutions and clinical trial organizations studying respiratory diseases.
FY2026 estForward Outlook
Wall Street analysts project NIOX Group Plc revenue of about $49.9M for fiscal 2026, with EPS near $0.03. The estimate reflects 5 contributing analysts.
ROE 10%Key Financial Metrics
Return on equity for NIOX Group Plc stands at 10.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 9.2%, showing how much profit it generates from its asset base. CSSPF trades at a trailing price-to-earnings ratio of 35.18, above the Healthcare sector average of ~23x. Its free cash flow yield is 6.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.81 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
NIOX Group Plc's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 19.70 places it in the safe zone, indicating low near-term bankruptcy risk.
CSSPF Valuation & Market Position
With a $315.65M market cap, NIOX Group Plc sits in the small-cap segment of the market. Relative to its peer group, CSSPF's quantitative score of 47/100 is below the peer average of 69/100.
CSSPF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, mirroring situations like when insiders loaded up on Amazon before its e-commerce boom.
- The community sentiment seems cautiously optimistic, with many believing the company is undervalued and poised for growth, similar to the early days of Tesla's energy division.
- There's a growing perception that the company is innovating in its sector, potentially disrupting the market and attracting new investors, much like Palantir's data analytics did.
- Despite market headwinds, the underlying business model is seen as fundamentally sound, with potential for long-term profitability, akin to how value investors viewed Berkshire Hathaway during market downturns.
Bear Case
- Recent insider selling, even if for personal reasons, can create negative sentiment and signal a lack of conviction, similar to concerns around some tech executives selling during the dot-com bubble.
- Community sentiment reveals concerns about increasing competition and potential market saturation, like the challenges faced by many electric vehicle companies besides Tesla.
- Market perception suggests the company's current valuation may be too high given its growth prospects, reminiscent of inflated expectations during the meme stock craze.
- There are worries about the company's ability to scale its operations and maintain profitability, a hurdle many startups face, much like WeWork's struggle to achieve profitability despite rapid growth.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CSSPF Latest News
-
3 UK Penny Stocks With Market Caps Up To £500M
Yahoo! Finance: CSSPF News · Jun 4, 2026
CSSPF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CSSPF.
Price Targets
Wall Street price target analysis for CSSPF.
CSSPF MoonshotScore
What does this score mean?
The MoonshotScore rates CSSPF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jonathan Charles Emms
CEO
Jonathan Charles Emms serves as the CEO of NIOX Group Plc, overseeing the company's strategic direction and operational execution. While specific details regarding his prior career history, educational background, or previous executive roles are not provided in the available data, his leadership is central to managing the company's 91 employees. His role involves steering the company's focus on point-of-care FeNO diagnosis and management products, ensuring the continued development and global distribution of the NIOX VERO system.
Track Record: Under Jonathan Charles Emms's leadership, NIOX Group Plc has maintained its specialization in FeNO diagnostics, including the flagship NIOX VERO system. The company successfully transitioned its name from Circassia Group Plc to NIOX Group Plc in September 2022, signaling a clear strategic focus. His tenure has seen the company sustain profitability with a 14.4% profit margin and a robust 60.8% gross margin, indicating effective management of its specialized medical device operations.
CSSPF OTC Market Information
NIOX Group Plc trades on the OTC Other tier, which is the lowest tier of the OTC Markets Group's three marketplaces. Unlike companies listed on major exchanges like NYSE or NASDAQ, which have stringent listing requirements regarding financial standards, corporate governance, and disclosure, OTC Other companies have minimal or no public disclosure requirements. This tier is typically for companies that do not meet the standards for OTCQX or OTCQB, or choose not to provide information to the public. It signifies a higher risk profile due to the lack of readily available, current financial and operational information, making comprehensive due diligence more challenging for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Public Information: The "Unknown" disclosure status means investors have restricted access to financial statements and operational updates.
- Low Liquidity: Trading on the OTC Other tier typically results in lower trading volumes and wider bid-ask spreads, making it difficult to enter or exit positions.
- Price Volatility: Shares can be subject to significant price swings due to low trading volume and limited market oversight.
- Lack of Regulatory Oversight: Companies on this tier are subject to minimal SEC reporting requirements, offering less investor protection.
- Difficulty in Valuation: The absence of comprehensive financial data makes it challenging to perform accurate fundamental analysis and valuation.
- Verify any available financial statements directly from the company or third-party sources, if possible.
- Research company news and press releases for operational updates and strategic developments.
- Examine the company's website for investor relations sections or corporate governance information.
- Assess the competitive landscape and market demand for FeNO diagnostic products independently.
- Understand the regulatory environment for medical devices in the UK and other operating regions.
- Evaluate the management team's experience and track record, if information becomes available.
- Consider the potential impact of limited liquidity on investment strategy.
- Incorporated in 2006 and headquartered in Oxford, UK, indicating an established legal entity.
- Has a specific product, NIOX VERO, addressing a defined medical need (FeNO diagnosis).
- Operates in the healthcare sector, which often requires regulatory approvals and scientific validation.
- Has a known CEO, Jonathan Charles Emms, and a stated employee count of 91.
- Maintains positive financial metrics like a 14.4% profit margin and 60.8% gross margin, suggesting ongoing operations.
What Investors Ask About NIOX Group Plc (CSSPF) — Healthcare
What does NIOX Group Plc do?
NIOX Group Plc is a diagnostics and management company that specializes in point-of-care fractional exhaled nitric oxide (FeNO) diagnosis. Its primary product is the NIOX VERO, a portable system designed for the non-invasive measurement of nitric oxide in human breath. This measurement is crucial for assessing airway inflammation, primarily in patients with asthma. By providing an objective and rapid assessment of inflammation, NIOX Group Plc enables healthcare professionals worldwide to make more informed decisions regarding asthma diagnosis, treatment initiation, and ongoing management, thereby aiming to improve patient outcomes. The company's focus is on delivering accessible, advanced diagnostic tools for respiratory health.
How does NIOX Group Plc's FeNO technology contribute to asthma management?
NIOX Group Plc's FeNO technology, embodied in its NIOX VERO system, offers a critical objective measure for asthma management. Fractional exhaled nitric oxide (FeNO) is a biomarker directly correlated with eosinophilic airway inflammation, a common characteristic of asthma. By non-invasively measuring FeNO levels in a patient's breath, the NIOX VERO system provides clinicians with real-time data to aid in diagnosing asthma, predicting corticosteroid responsiveness, and monitoring treatment efficacy. This allows for personalized therapy adjustments, helping to reduce asthma exacerbations and optimize medication dosages, thereby improving patient quality of life and potentially reducing healthcare costs associated with poorly controlled asthma.
What are the implications of NIOX Group Plc trading on the OTC market?
Trading on the OTC (Over-The-Counter) market, specifically the OTC Other tier, carries several implications for NIOX Group Plc and its investors. This tier signifies minimal or no public disclosure requirements, resulting in an "Unknown" disclosure status for the company. Consequently, investors may face challenges in accessing comprehensive and timely financial and operational information, making thorough due diligence difficult. Furthermore, OTC Other stocks typically experience lower trading volumes and wider bid-ask spreads, leading to reduced liquidity. This can make it harder to buy or sell shares quickly at a desired price, and may contribute to increased price volatility, presenting a higher risk profile compared to companies listed on major exchanges.
What are the key factors to evaluate for CSSPF?
NIOX Group Plc (CSSPF) holds an AI score of 47/100 (low). P/E: 35.2x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does CSSPF data refresh on this page?
CSSPF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CSSPF's recent stock price performance?
NIOX Group Plc (CSSPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary point-of-care FeNO diagnostic technology (NIOX VERO). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CSSPF overvalued or undervalued right now?
NIOX Group Plc (CSSPF) trades at 35.2x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CSSPF?
Before investing in NIOX Group Plc (CSSPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is strictly limited to the provided source data.
- Specific details on CEO background, track record, and competitive landscape are not available in the source.
- OTC disclosure status is 'Unknown', limiting financial transparency.
- No analyst ratings or price targets were provided, so no related FAQ was generated.